Effect ol losartan on circulating TNF alpha levels and left ventricular systolic performance in patients with heart failure

Gurlek A., Kilickap M., DİNÇER İ., Dandachi R., Tutkak H., Oral D.

JOURNAL OF CARDIOVASCULAR RISK, vol.8, no.5, pp.279-282, 2001 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 5
  • Publication Date: 2001
  • Doi Number: 10.1097/00043798-200110000-00006
  • Journal Name: JOURNAL OF CARDIOVASCULAR RISK
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.279-282
  • Keywords: ejection fraction, losartan, systolic function, tumor necrosis factor alpha, TUMOR-NECROSIS-FACTOR, CHRONIC-RENAL-FAILURE, ECHOCARDIOGRAPHIC ACOUSTIC QUANTIFICATION, ANGIOTENSIN-II, EJECTION FRACTION, EXERCISE CAPACITY, RANDOMIZED TRIAL, CLINICAL STATUS, PLASMA-LEVELS, WALL-MOTION
  • Ankara University Affiliated: No

Abstract

Background Tumor necrosis factor alpha (TNF alpha) plays an important role in the pathophysiology of heart failure. Recent studies have shown a beneficial effect of losartan in these patients. However, the effect of losartan on TNF alpha levels in heart failure has not yet been studied. We evaluated the effect of losartan on circulating TNF alpha levels and ejection fraction (EF) in patients with congestive heart failure.